Compare SILO & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SILO | JAGX |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 2.5M |
| IPO Year | 2011 | 2014 |
| Metric | SILO | JAGX |
|---|---|---|
| Price | $1.22 | $4.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.2K | ★ 4.6M |
| Earning Date | 11-12-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.98 | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | $72,102.00 | ★ $11,511,000.00 |
| Revenue This Year | N/A | $77.78 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.30 | $0.20 |
| 52 Week High | $19.92 | $41.53 |
| Indicator | SILO | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 18.63 | 49.11 |
| Support Level | N/A | $1.15 |
| Resistance Level | $4.80 | $7.63 |
| Average True Range (ATR) | 0.12 | 2.04 |
| MACD | 0.04 | -0.48 |
| Stochastic Oscillator | 20.34 | 2.10 |
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.